|Targets||Isocitrate Dehydrogenase (IDH)|
|Description||GSK864 is a cell penetrant, selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant with IC50 values of 8.8, 15.2 and 16.6 nM for IDH1 mutants R132C, R132H, and R132G, respectively.|
|Synonyms||(7S)-1-[(4-fluorophenyl)methyl]-3-N-(4-methoxy-3,5-dimethylphenyl)-7-methyl-5-(1H-pyrrole-2-carbonyl)-4,6-dihydropyrazolo[4,3-c]pyridine-3,7-dicarboxamide; GSK 864; GSK-864|
|Solubility||DMSO: ≥ 100 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||782.9±60.0 ℃ at 760 Torr|
Mutant IDH1-IN-2, aslo called as SCHEMBL14831158, is an inhibitor of mutant IDH protein. It is developed for the treatment of diseases associated with such muta...
GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50= 4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 st...
TC-E 5008 is a selective and cancer-associated mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor (Ki = 120-190 nM), displaying >60-fold selectivity for mIDH1 ...
Mutant IDH1-IN-1, a mutant IDH1 R132H inhibitor, could be used in some biological studies.
Ivosidenib, also called AG-120, is an oral inhibitor that specifically inhibits a mutated form of IDH1 in the cytoplasm.
SCHEMBL14831541, also called as Mutant IDH1 inhibitor, is an inhibitor of mutant IDH1 which is key enzymes found in cellular metabolism.
Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2).
GSK864 is a cell penetrant, selective allosteric inhibitor of isocitrate dehydrogenase 1 (IDH1) mutant with IC50 values of 8.8, 15.2 and 16.6 nM for IDH1 mutant...
Alpha-mangostin, a prenylated xanthone derivative from Mangosteen, Garcinia mangostana L. (Clusiaceae), has shown to possess diverse pharmacological activities ...
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
Enasidenib mesylate is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes indicated for the treatment of adult patients ...